- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
46 result(s) found for: Purine.
Displaying page 1 of 3.
EudraCT Number: 2013-000975-33 | Sponsor Protocol Number: RDCRN_RKSC_6412 | Start Date*: 2013-11-19 |
Sponsor Name:Landspitali - The National University Hospital of Iceland | ||
Full Title: Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1 | ||
Medical condition: Adenine phosphoribosyltransferase deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003046-27 | Sponsor Protocol Number: HCL-PG03 | Start Date*: 2014-09-27 |
Sponsor Name:Dipartimento di Medicina | ||
Full Title: A PHASE II OPEN-LABEL SINGLE-CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR VEMURAFENIB (ZELBORAF) IN COMBINATION WITH THE B-CELL TARGETING ANTIBODY RITUXIMAB (MABTHERA... | ||
Medical condition: HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001669-27 | Sponsor Protocol Number: CLLX2 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:Universitätsklinikum Heidelberg | |||||||||||||
Full Title: A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study G... | |||||||||||||
Medical condition: High-risk and very high-risk chronic lymphocytic leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005487-13 | Sponsor Protocol Number: HCL-PG01 | Start Date*: 2012-05-11 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | |||||||||||||
Full Title: A phase II, multi-center, open label study of the clinical activity and safety of the BRAF-V600 inhibitor vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia (HCL) carry... | |||||||||||||
Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600 mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001379-29 | Sponsor Protocol Number: HCL-PG02 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:Dipartimento di Medicina | |||||||||||||
Full Title: A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING... | |||||||||||||
Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600E mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003631-36 | Sponsor Protocol Number: RG_12-124 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005317-68 | Sponsor Protocol Number: ACE-CL-208 | Start Date*: 2016-05-16 | |||||||||||
Sponsor Name:Acerta Pharma B.V. | |||||||||||||
Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | |||||||||||||
Medical condition: High Risk Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002405-61 | Sponsor Protocol Number: IPI-145-07 | Start Date*: 2014-02-20 | |||||||||||
Sponsor Name:Infinity Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) HU (Completed) IT (Ongoing) GB (Completed) BE (Completed) AT (Completed) DE (Completed) LV (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000694-23 | Sponsor Protocol Number: PCYC-1112-CA | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:Pharmacyclics LLC an Abbvie Company | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia... | |||||||||||||
Medical condition: relapsed or refractory CLL/SLL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001833-29 | Sponsor Protocol Number: 202152 | Start Date*: 2016-09-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and... | |||||||||||||
Medical condition: Active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000568-32 | Sponsor Protocol Number: CLLTX1 | Start Date*: 2017-11-07 | ||||||||||||||||
Sponsor Name:Universität Köln | ||||||||||||||||||
Full Title: Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation | ||||||||||||||||||
Medical condition: Patients with poor risk CLL and Richter`s transformation requiring an allogeneic stem cell transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001947-31 | Sponsor Protocol Number: TUD-CLL-X4-054 | Start Date*: 2013-02-27 | |||||||||||
Sponsor Name:Technische Universität Dresen | |||||||||||||
Full Title: Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial | |||||||||||||
Medical condition: Patients aged >55 years with a diagnosis of CLL according to WHO criteria confirmed by flow cytometry of peripheral blood or bone marrow and a poor-risk disease according to the EBMT CLL Transplan... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003608-11 | Sponsor Protocol Number: RG_12-125 | Start Date*: 2014-02-20 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL. | |||||||||||||
Medical condition: Chronic Lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001836-20 | Sponsor Protocol Number: HCL-PG04 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA | |||||||||||||
Full Title: STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARM... | |||||||||||||
Medical condition: HCL patients carrying the BRAF-V600E mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023022-20 | Sponsor Protocol Number: CLL2S | Start Date*: 2011-08-03 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Ulm | ||||||||||||||||||
Full Title: A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agen... | ||||||||||||||||||
Medical condition: CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analogues | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001626-27 | Sponsor Protocol Number: CC-5013-CLL-002 | Start Date*: 2009-04-14 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHR... | |||||||||||||
Medical condition: Relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) who have achieved at least partial response (PR) to second-line therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) ES (Completed) HU (Completed) CZ (Completed) PT (Completed) AT (Completed) IT (Completed) DK (Completed) FR (Completed) SE (Completed) NL (Completed) IE (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005186-20 | Sponsor Protocol Number: 7965-012 | Start Date*: 2012-07-12 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation. | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
Medical condition: chronic lymphocytic leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) CZ (Completed) SE (Completed) FI (Completed) LT (Prematurely Ended) LV (Completed) ES (Completed) HU (Completed) IT (Completed) PL (Prematurely Ended) BE (Prematurely Ended) GR (Completed) EE (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003233-26 | Sponsor Protocol Number: CD-ON-CAT-8015-1053 | Start Date*: 2015-04-13 | ||||||||||||||||
Sponsor Name:MedImmune, LLC | ||||||||||||||||||
Full Title: A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia | ||||||||||||||||||
Medical condition: Hairy Cell Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) BE (Completed) IE (Completed) DE (Completed) CZ (Completed) PL (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006292-20 | Sponsor Protocol Number: GS-US-312-0115 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chroni... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002850-31 | Sponsor Protocol Number: AP3005 | Start Date*: 2006-08-31 | |||||||||||
Sponsor Name:TopoTarget A/S | |||||||||||||
Full Title: APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic he... | |||||||||||||
Medical condition: The medical condition for this clinical trial is B. cell chronic lymphocytic leukemia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.